-
公开(公告)号：US20120212017A1
公开(公告)日：2012-08-23
申请号：US13371940
申请日：2012-02-13
CPC分类号： B60N2/4847 , B60N2/4221 , B60N2/42745 , B60N2/844 , B60N2/847 , B60N2/888
摘要： A headrest including: a headrest body that supports a head portion of an occupant; a pair of side frame sections that supports the headrest body, the side frame sections extending along a seat height direction and disposed at a separation from each other along a seat width direction; and an inclined wall portion that is provided between the side frame sections, that is inclined towards a seat front-rear direction front side with respect to the side frame sections such that a lower end portion of the inclined wall portion is positioned further to the seat front-rear direction front side than an upper end portion of the inclined wall portion, and that bears load acting on the headrest body from a seat front-rear direction rear side.
摘要翻译： 头枕包括：头枕主体，其支撑乘员的头部; 一对侧框架部分，其支撑所述头枕本体，所述侧框架部分沿着座椅高度方向延伸并沿着座椅宽度方向彼此分离设置; 以及设置在所述侧框架部之间的倾斜壁部，所述倾斜壁部相对于所述侧框架部朝向座椅前后方向前侧倾斜，使得所述倾斜壁部的下端部位于所述座部 前后方向前倾侧壁部的上端部，并且从座椅前后方向后侧承受作用在头枕主体上的负荷。
-
公开(公告)号：US20100022542A1
公开(公告)日：2010-01-28
申请号：US12504604
申请日：2009-07-16
IPC分类号： A61K31/5377 , C07D277/00 , A61K31/425 , C07D417/02 , A61K31/4439 , A61P7/02
CPC分类号： C07D285/16 , A61K31/426 , A61K31/427 , A61K31/4439 , A61K31/5377 , C07D231/40 , C07D249/14 , C07D277/46 , C07D277/82 , C07D285/18 , C07D333/38 , C07D417/04 , C07D417/14
摘要： Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: X1—Y1-Z1-W1 (I) wherein X1 is optionally substituted aryl, optionally substituted heteroaryl or the like; Y1 is —NRACO—(CH2)0-2— or the like (wherein RA is a hydrogen or the like); Z1 is optionally substituted phenylene or the like; and W1 is a group represented by the below formula: wherein R1, R2, R3, and R4 are each independently a hydrogen atom, optionally substituted lower alkyl or the like, a broken line (---) represents the presence or absence of bond.
摘要翻译： 含有通式（I）的化合物，其前药，二者的药学上可接受的盐或它们的溶剂化物并显示血小板生成素受体激动作用的药物组合物：X1-Y1-Z1-W1（Ⅰ）其中X1是 任选取代的芳基，任选取代的杂芳基等; Y1是-NRACO-（CH 2）0-2-等（其中RA是氢等）; Z1是任选取代的亚苯基等; 并且W1是由下式表示的基团：其中R1，R2，R3和R4各自独立地为氢原子，任选取代的低级烷基等，虚线（---）表示存在或不存在键 。
-
公开(公告)号：US20120123114A1
公开(公告)日：2012-05-17
申请号：US13359326
申请日：2012-01-26
申请人： Masaharu KUME , Kenji MATSUO , Naoki OMORI , Masami TAKAYAMA , Aiko OMORI , Takeshi ENDO
发明人： Masaharu KUME , Kenji MATSUO , Naoki OMORI , Masami TAKAYAMA , Aiko OMORI , Takeshi ENDO
IPC分类号： C07D417/12 , C07D239/94 , C07D403/12 , C07D413/12 , C07D405/12 , C07D405/14 , C07D417/14 , C07D413/14 , C07D403/14 , C07D401/12 , C07D401/14
CPC分类号： C07D239/94 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D407/12 , C07D417/12
摘要： A compound which inhibits both of EGF receptor tyrosine kinase and HER2 tyrosine kinase is provided.A compound represented by the general formula (I): wherein RX is a group represented by the formula: wherein R1 is a hydrogen atom, optionally substituted alkyl, etc.; Z is —O—, —N(R10)—, etc.; R10 is a hydrogen atom, alkyl, etc.; R2 is a hydrogen atom, optionally substituted alkyl, etc.; R18 is a hydrogen atom, optionally substituted alkyl, etc.; R19 is optionally substituted alkyl, etc.; W1 is an optionally substituted non-aromatic nitrogen-containing group; R17 is a hydrogen atom, optionally substituted alkyl, etc.; R3 and R4 are independently a hydrogen atom, optionally substituted alkyl, etc.; X is —O—, —S—, or —N(R12)—, etc.; R12 is a hydrogen atom, alkyl, etc.; and A is phenyl optionally having a substituent, etc., its pharmaceutically acceptable salt, or a solvate thereof.
摘要翻译： 提供抑制EGF受体酪氨酸激酶和HER2酪氨酸激酶两者的化合物。 由通式（I）表示的化合物：其中RX是由下式表示的基团：其中R1是氢原子，任选取代的烷基等; Z是-O - ， - N（R 10） - 等; R10是氢原子，烷基等; R2是氢原子，任选取代的烷基等; R18是氢原子，任意取代的烷基等; R19是任选取代的烷基等; W1是任选取代的非芳族含氮基团; R 17是氢原子，任选取代的烷基等; R3和R4独立地是氢原子，任选取代的烷基等; X是-O-，-S-或-N（R 12） - 等; R12是氢原子，烷基等; 和A是任选具有取代基的苯基等，其药学上可接受的盐或其溶剂合物。
-
-
搜索结果
3 条记录 (耗时 0.027 秒)